Pilar
Nos Mateu
Publikationen, an denen er mitarbeitet Pilar Nos Mateu (22)
2024
-
Efficacy of Beclomethasone Dipropionate in Lowering Fecal Calprotectin Levels in Patients with Ulcerative Colitis in Clinical Remission and at Risk of Relapse: The Becalcu Randomized, Controlled Trial
Digestive Diseases
-
Need for therapeutic escalation in patients with refractory ulcerative proctitis: Results from the PROCU study of the ENEIDA registry
Alimentary Pharmacology and Therapeutics, Vol. 60, Núm. 5, pp. 604-612
2021
-
Corrigendum to “Recomendaciones del Grupo Español de Trabajo en enfermedad de Crohn y colitis ulcerosa (GETECCU) sobre la reservoritis en la colitis ulcerosa. Parte 2: Tratamiento” [Gastroenterología y Hepatología 2020;43(10):649-658](S0210570520301606)(10.1016/j.gastrohep.2020.04.004)
Gastroenterologia y Hepatologia
2020
-
Antitumor Necrosis Factor Agents to Treat Endoscopic Postoperative Recurrence of Crohn's Disease: A Nationwide Study With Propensity-Matched Score Analysis
Clinical and translational gastroenterology, Vol. 11, Núm. 8, pp. e00218
-
Real-world long-term effectiveness of ustekinumab in Crohn's disease: results from the ENEIDA registry
Alimentary Pharmacology and Therapeutics, Vol. 52, Núm. 6, pp. 1017-1030
-
Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on pouchitis in ulcerative colitis. Part 2: Treatment
Gastroenterologia y Hepatologia, Vol. 43, Núm. 10, pp. 649-658
2019
-
Anti-tumour necrosis factor discontinuation in inflammatory bowel disease patients in remission: study protocol of a prospective, multicentre, randomized clinical trial
Therapeutic Advances in Gastroenterology, Vol. 12
-
EpidemIBD: rationale and design of a large-scale epidemiological study of inflammatory bowel disease in Spain
Therapeutic Advances in Gastroenterology, Vol. 12
-
Increased risk of thiopurine-related adverse events in elderly patients with IBD
Alimentary Pharmacology and Therapeutics, Vol. 50, Núm. 7, pp. 780-788
-
Management of acute severe ulcerative colitis in Spain: A nationwide clinical practice survey
Gastroenterologia y Hepatologia, Vol. 42, Núm. 2, pp. 90-101
-
Real-world short-term effectiveness of ustekinumab in 305 patients with Crohn’s disease: results from the ENEIDA registry
Alimentary Pharmacology and Therapeutics, Vol. 50, Núm. 3, pp. 278-288
-
Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on pouchitis in ulcerative colitis. Part 1: Epidemiology, diagnosis and prognosis
Gastroenterologia y Hepatologia, Vol. 42, Núm. 9, pp. 568-578
2018
-
Reviewing the therapeutic role of budesonide in Crohn's disease
Gastroenterologia y Hepatologia
2017
-
Effectiveness of adalimumab for the treatment of ulcerative colitis in clinical practice: comparison between anti-tumour necrosis factor-naïve and non-naïve patients
Journal of Gastroenterology, Vol. 52, Núm. 7, pp. 788-799
-
Erratum to: Effectiveness of adalimumab for the treatment of ulcerative colitis in clinical practice: comparison between anti-tumour necrosis factor-naïve and non-naïve patients (J Gastroenterol, 10.1007/s00535-016-1274-1)
Journal of Gastroenterology
2014
-
Disease severity in familial cases of IBD
Journal of Crohn's and Colitis, Vol. 8, Núm. 3, pp. 234-239
-
Risk of colectomy in patients with ulcerative colitis under thiopurine treatment
Journal of Crohn's and Colitis, Vol. 8, Núm. 10, pp. 1287-1293
2013
-
Observational study on the efficacy of adalimumab for the treatment of ulcerative colitis and predictors of outcome
Journal of Crohn's and Colitis, Vol. 7, Núm. 9, pp. 717-722
-
Smoking does influence disease behaviour and impacts the need for therapy in Crohn′s disease in the biologic era
Alimentary Pharmacology and Therapeutics, Vol. 38, Núm. 7, pp. 752-760
2012
-
Long-term durability of response to adalimumab in Crohn's disease
Inflammatory Bowel Diseases, Vol. 18, Núm. 4, pp. 685-690